China Resources Pharmaceutical Group (3320) H1 2026 earnings summary

Executive summary

• Maintained leading position in China's pharmaceutical industry, ranking second in manufacturing and third in distribution by revenue for H1 2026.

• Revenue rose 2.0% year-over-year to RMB134,457.6 million for the six months ended 30 June 2026, with net profit at RMB5,023.5 million, down 0.6% year-over-year.

• Focused on R&D innovation, external M&A, digital transformation, and green development to drive high-quality, sustainable growth.

• Enhanced business structure and operational quality, with strategic expansion in emerging industries and international markets.

• Interim dividend declared at RMB0.087 per share, a 21% increase year-over-year.

Financial highlights

• Total revenue reached RMB134,457.6 million, up 2.0% year-over-year; gross profit was RMB21,534.1 million, up 0.1%.

• Net profit was RMB5,023.5 million, down 0.6% year-over-year; profit attributable to owners/shareholders rose 5.3% to RMB2,186.6 million.

• Basic EPS was RMB0.35 (vs. RMB0.33 in H1 2025); interim dividend declared at RMB0.087 per share, up 21%.

• Pharmaceutical manufacturing revenue: RMB24,444.7 million (-1.5% YoY), gross margin 60.3% (+1.0ppt).

• Distribution revenue: RMB110,994.8 million (+2.5% YoY), gross margin 5.7% (-0.2ppt); retail revenue: RMB6,337.2 million (+14.9% YoY), gross margin 6.3% (+0.2ppt).

Outlook and guidance

• Will focus on strategic emerging industries (biologics, blood products, high-end medical devices, synthetic biology) and optimize business structure.

• Plans to strengthen R&D, accelerate innovation, and pursue both internal quality improvement and external expansion.

• Aims to consolidate industry position, enhance operational excellence, and leverage digital technologies for business upgrades.